嵌合抗原受体T细胞治疗的心血管毒性

董斐斐; 傅维佳; 秦永文; 赵仙先

doi:10.13201/j.issn.1001-1439.2020.01.018

嵌合抗原受体T细胞治疗的心血管毒性

- 1. 海军军医大学第一附属医院心血管内科(上海, 200433);
- 2. 海军军医大学第一附属医院血液内科
基金项目:
国家自然科学基金面上项目(No:81570208)

详细信息

通讯作者: 赵仙先,E-mail:zhaoxx1112@126.com

中图分类号: R541.7

收稿日期: 2019-07-05

Cardiotoxicity of chimeric antigen receptor T cell therapy

- 1. Department of Cardiology;
- 2. Department of Hematology, the First Affiliated Hospital of Naval Military Medical University, Shanghai, 200433, China

More Information

Corresponding author: ZHAO Xianxian, E-mail: zhaoxx1112@126.com

Received Date: 05 July 2019

摘要

摘要: 近年来,免疫疗法已成为继手术、放疗和化疗之后的第4种肿瘤治疗手段。其中,嵌合抗原受体(chimeric antigen receptor,CAR)T细胞免疫治疗在复发/难治的急、慢性淋巴细胞白血病及非霍奇金淋巴瘤治疗上取得了令人瞩目的成绩。然而该疗法在临床应用过程中,出现了诸如低血压、心律失常、心力衰竭等多种心脏毒性表现,严重时危及生命,限制了该疗法的适应证。本文通过介绍CAR-T细胞疗法的心血管毒性的发生机制、临床表现、处理方法等,为识别高危患者、增加治疗安全性、减少心血管不良事件的发生提供参考。
- 嵌合抗原受体 /
- 免疫治疗 /
- 白血病 /
- 心脏毒性
Abstract: In recent years,immunotherapy has become the fourth treatment against cancer aside from surgery,radiotherapy and chemotherapy.Chimeric antigen receptor T cell immunotherapy has made remarkable achievements in the treatment of recurrent/refractory acute and chronic lymphocytic leukemia and non-Hodgkin's lymphoma.However,in the course of clinical application,potentially life-threatening cardiotoxicities manifested as hypotension,arrhythmia and heart failure limit the indication of the treatment.This artical introduces the mechanism,clinical manifestation and management of cardiotoxicities raised by CAR-T cell therapy for identifying high risk patients,increasing the safety of treatment and reducing the occurrence of cardiovascular adverse events.
- chimeric antigen receptor /
- immunotherapy /
- leukemia /
- cardiotoxicity

HTML全文

参考文献(34)

[1]	Asnani A.Cardiotoxicity of immunotherapy:incidence,diagnosis,and management[J].Curr Oncol Rep,2018,20(6):44.
[2]	Brudno JN,Kochenderfer JN.Recent advances in CAR T-cell toxicity:Mechanisms,manifestations and management[J].Blood Rev,2019,34:45-55.
[3]	Lee DW,Kochenderfer JN,Stetler-Stevenson M,et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults:a phase 1 dose-escalation trial[J].Lancet,2015,385(9967):517-528.
[4]	Bonifant CL,Jackson HJ,Brentjens RJ,et al.Toxicity and management in CAR T-cell therapy[J].Mol Ther Oncolytics,2016,3:16011.
[5]	Ali SA,Shi V,Maric I,et al.T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma[J].Blood,2016,128(13):1688-1700.
[6]	Brudno JN,Somerville RP,Shi V,et al.Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease[J].J Clin Oncol,2016,34(10):1112-1121.
[7]	Kochenderfer JN,Somerville RPT,Lu T,et al.Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels[J].J Clin Oncol,2017,35(16):1803-1813.
[8]	Brudno JN,Maric I,Hartman SD,et al.T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma[J].J Clin Oncol,2018,36(22):2267-2280.
[9]	Burstein DS,Maude S,Grupp S,et al.Cardiac profile of chimeric antigen receptor T cell therapy in children:a single-institution experience[J].Biol Blood Marrow Transplant,2018,24(8):1590-1595.
[10]	Moslehi JJ.Cardiovascular toxic effects of targeted cancer therapies[J].N Engl J Med,2016,375(15):1457-1467.
[11]	郭琳娟,俞建华,李菊香,等.持续静脉缓慢滴注和静脉推注降低蒽环类药物心脏毒性风险的荟萃分析[J].临床心血管病杂志,2017,33(1):34-39.
[12]	赖玮,帅维,洪葵.肿瘤药物治疗引发的心功能不全的心脏评估[J].临床心血管病杂志,2016,32(3):221-224.
[13]	Davila ML,Riviere I,Wang X,et al.Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J].Sci Transl Med,2014,6(224):224ra25.
[14]	Gross G,Eshhar Z.Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment:counteracting off-tumor toxicities for safe CAR T cell therapy[J].Annu Rev Pharmacol Toxicol,2016,56:59-83.
[15]	Zheng PP,Li J,Kros JM.Breakthroughs in modern cancer therapy and elusive cardiotoxicity:Critical research-practice gaps,challenges,and insights[J].Med Res Rev,2018,38(1):325-376.
[16]	Kizhedath A,Wilkinson S,Glassey J.Applicability of predictive toxicology methods for monoclonal antibody therapeutics:status quo and scope[J].Arch Toxicol,2017,91(4):1595-1612.
[17]	Linette GP,Stadtmauer EA,Maus MV,et al.Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma[J].Blood,2013,22(6):863-871.
[18]	Cameron BJ,Gerry AB,Dukes J,et al.Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells[J].Sci Transl Med,2013,5(197):197ra03.
[19]	Fitzgerald JC,Weiss SL,Maude SL,et al.Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia[J].Crit Care Med,2017,45(2):e124-e131.
[20]	Giavridis T,van der Stegen SJC,Eyquem J,et al.CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade[J].Nat Med,2018,24(6):731-738.
[21]	DeFrancesco L.CAR-T cell therapy seeks strategies to harness cytokine storm[J].Nat Biotechnol,2014,32(7):604.
[22]	Bonifant CL,Jackson HJ,Brentjens RJ,et al.Toxicity and management in CAR T-cell therapy[J].Mol Ther Oncolytics,2016,3:16011.
[23]	Brudno JN,Kochenderfer JN.Toxicities of chimeric antigen receptor T cells:recognition and management[J].Blood,2016,127(26):3321-3330.
[24]	Le RQ,Li L,Yuan W,et al.FDA approval summary:Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome[J].Oncologist Aug,2018,23(8):943-947.
[25]	Schuster SJ,Svoboda J,Chong EA,et al.Chimeric antigen receptor T cells in refractory B-cell lymphomas[J].N Engl J Med,2017,377(26):2545-2554.
[26]	Teachey DT,Lacey SF,Shaw PA,et al.Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia[J].Cancer Discov,2016,6(6):664-679.
[27]	Singh N,Hofmann TJ,Gershenson Z,et al.Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function[J].Cytotherapy,2017,19(7):867-880.
[28]	Brudno JN,Maric I,Hartman SD,et al.T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma[J].J Clin Oncol Aug 1,2018,36(22):2267-2280.
[29]	Kochenderfer JN,Somerville RPT,Lu T,et al.Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels[J].J Clin Oncol,2017,35(16):1803-1813.
[30]	Lee DW,Gardner R,Porter DL,et al.Current concepts in the diagnosis and management of cytokine release syndrome[J].Blood,2014,124(2):188-195.
[31]	Porter DL,Hwang WT,Frey NV,et al.Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia[J].Sci Transl Med,2015,7(303):303ra139.
[32]	李亮,王梅,刘涛等.扩张型心肌病的免疫治疗研究进展[J].临床心血管病杂志,2017,33(11):1031-1035.
[33]	Teachey DT,Bishop MR,Maloney DG,et al.Toxicity management after chimeric antigen receptor T cell therapy:one size does not fit 'ALL'[J].Nat Rev Clin Oncol,2018,15(4):218.
[34]	Neelapu SS,Tummala S,Kebriaei P,et al.Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J].Nat Rev Clin Oncol,2018,15(1):47-62.